Shivalik Rasayan Limited — Important, 10-12-2024: Updates

Shivalik Rasayan Limited's Board has approved the unaudited financial results for the quarter and half-year ending September 30, 2024. The company's strategic focus remains on expanding its position in the agro-chemical and API markets, leveraging India’s growing share globally.

**Financial Highlights:** The recently launched 2000 MT capacity block for insecticides and fungicides at the newly operational facility in Dahej is anticipated to significantly boost production capabilities, with Dimethoate technical capacity rising from 1450 MTPA to 5000 MTPA.

**Strategic Initiatives and Growth Drivers:** Shivalik continues to enhance its API offerings, having received US FDA approval for its Dahej facility in October. The firm plans to capitalize on international export opportunities, particularly in regulated markets such as the US and Europe.

**Business Developments:** The commissioning of the new agro and specialty chemicals plant in Dahej, which commenced operations in September 2024, marks a significant expansion in production capacity and showcases the company’s aggressive growth strategy.

**Market Position and Competitive Advantage:** With a strong research and development focus and a robust pipeline of products under development, Shivalik is positioned to take advantage of expiring patents and the international demand for CDMO services.

**Investor Implications:** These developments imply a positive outlook, with potential for enhanced revenue streams as new markets open up for both APIs and agrochemicals, supported by the company's strategic investments in production and R&D.